Martin Foerster

Martin Foerster

Auto-generated profile, based on publicly available information

Martin Foerster

Department of Chemical Engineering, Monash University, Clayton, Victoria 3800, Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MFMartin Foerster
Martin Foerster
TGThomas Gengenbach
Thomas Gengenbach
Meng Wai WooMeng Wai Woo
Meng Wai Woo
CSCordelia Selomulya
Cordelia Selomulya

1 July 2013 in Chemical Engineering Journal
Verified
Journal Article
Closed access
MFM. Foerster
M. Foerster
KLK.F. Lam
K.F. Lam
ESE. Sorensen
E. Sorensen
AGAsterios Gavriilidis
Asterios Gavriilidis

1 December 2008 in Chinese Medical Journal
Verified
Journal Article
Open access
FMFritzenwanger Michael
Fritzenwanger Michael
FMFoerster Martin
Foerster Martin
MKMeusel Katharina
Meusel Katharina
JCJung Christian
Jung Christian
HFHans R. Figulla
Hans R. Figulla
In addition to elevated concentrations of cytokines, patients with congestive heart failure (CHF) show endothelial dysfunction and increased plasma concentrations of adhesion molecules like intercellular adhesion molecule-1 (ICAM-1). Furthermore, the concentration of cardiotrophin-1 (CT-1) -a cytokine of the interleukin-6 superfamily - is increased in CHF. We tested the hypothesis whether CT-1 is able to induce ICAM-1 in human umbilical vein endothelial cells (HUVEC). Furthermore we examined the signalling mechanisms of CT-1 mediated ICAM-1 expression. Confluent layers of HUVEC were incubated with increasing concentrations of CT-1 (5 to 100 ng/ml) for different periods. ICAM-1 mRNA was determined by real-time polymerase chain reaction (PCR) and ICAM-1 surface expression by fluorescence-activated cell sorter (FACS) analysis and soluble ICAM-1 (sICAM-1) in the culture supernatant by enzyme linked immunosorbent assay (ELISA). To clarify the signalling pathway of CT-1 induced ICAM-1 expression we used various inhibitors of possible signal transducing molecules, electromobility shift assay (EMSA) and Western blot analysis. CT-1 induced ICAM-1 mRNA (1.8±0.8 fold increase compared to unstimulated cells after 6 hours) and protein (1.4±0.2 fold increase compared to unstimulated cells after 48 hours) in HUVEC in a time- and concentration-dependent manner. EMSA experiments show that CT-1 causes nuclear factor (NF) κB activation. Because parthenolide could inhibit CT-1 induced ICAM-1 expression NFκB activation is required in this pathway. CT-1 did not activate extracellular signal regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and p38. CT-1 is able to induce ICAM-1 in endothelial cells by NFκB activation. These results may explain in part elevated ICAM-1 concentrations in patients with CHF and endothelial dysfunction.